According to GSK Singapore, the Health Sciences Authority (HSA) has approved Trelegy Ellipta fluticasone furoate / umeclidinium / vilanterol DPI for the treatment of asthma in adult patients who cannot control symptoms with a LABA / ICS combination. Trelegy Ellipta in a 100 / 62.5 / 25 mcg dosage strength was already approved for the treatment of COPD in Singapore; the new approval adds a 200 / 62.5 / 25 mcg dosage strength for the asthma indication only.
In the US, the FDA expanded the use of Trelegy Ellipta to add the asthma indication in 2020. In Europe, GSK also submitted an application to the EMA in 2020 to add the asthma indication; however, the EMA declined to approve that change.
GSK Singapore Country Medical Director Stephanie Ambrose commented, “There are over 200,000 adults living with asthma in Singapore. Among them, roughly 25% are treated with ICS/LABA, and within this group, almost 60% . . . still experience partly-controlled or uncontrolled symptoms. With this latest approval, we are pleased to share that this group of adults will potentially benefit from Trelegy and can look forward to having better control over their symptoms.”
Read the GSK press release.
